|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Aastrom Biosciences Inc., of Ann Arbor, Mich., said that it has expanded the Phase I/II trial of its adult stem cell-based tissue repair cells in the treatment of severe long bone or non-union fractures to include the University of Nebraska Medical Center in Omaha.
Adams Respiratory Therapeutics Inc., of Chester, N.J., priced its initial public offering of nearly 8 million shares at $17 each, raising gross proceeds of about $135.2 million. Of the shares being sold, 5.7 million come from Adams, while 2.25 million come from certain selling stockholders. The underwriters, Merrill Lynch & Co., Morgan Stanley, Deutsche Bank Securities and RBC Capital Markets, have an ...